Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL528132 | 1.00 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| P-Xylene SCHEMBL8660591 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL1705904 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL5068661 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL31313 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL29991938 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL11432043 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL34 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL6621981 | 0.87 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| Methoxymethane SCHEMBL3404680 | 0.86 | GAA (0.54) | ALDH1A1SMN1; SMN2LMNAGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0318393-A1 | Use of ademetionine against ageing of the skin | ELF SANOFI (FR) | 1989-05-31 | — | — | EP | claimed |
| US-11752123-B2 | Compositions comprising theanine, s-adenosylmethionine (SAMe), and/or magnolia and phellodendron | NUTRAMAX LABORATORIES, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230157984-A1 | COMPOSITIONS COMPRISING THEANINE, MAGNOLIA, AND PHELLODENDRON | NUTRAMAX LAB INC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2021106004-A1 | PHARMACEUTICAL COMPOSITION OF S-ADENOSYLMETHIONINE | KUSUM HEALTHCARE PVT. LTD. (IN) | 2021-06-03 | — | — | WO | disclosed |
| US-20210137870-A1 | COMPOSITIONS COMPRISING THEANINE, S-ADENOSYLMETHIONINE (SAMe), AND/OR MAGNOLIA AND PHELLODENDRON | NUTRAMAX LAB INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-10940130-B2 | Compositions comprising theanine and whey protein | NUTRAMAX LABORATORIES, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| EP-3662919-A1 | COMPOSITIONS COMPRISING MAGNOLIA, PHELLODENDRON, THEANINE AND/OR WHEY PROTEIN | NUTRAMAX LABORATORIES, INC. (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20190290608-A1 | COMPOSITIONS COMPRISING MAGNOLIA, PHELLODENDRON, THEANINE AND/OR WHEY PROTEIN | NUTRAMAX LAB INC (US) | 2019-09-26 | — | — | US | disclosed |
| US-10335384-B2 | Compositions comprising magnolia, phellodendron, theanine and/or whey protein | NUTRAMAX LABORATORIES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3344273-A1 | COMPOSITIONS COMPRISING MAGNOLIA, PHELLODENDRON, THEANINE AND/OR WHEY PROTEIN | NUTRAMAX LABORATORIES, INC. (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2009008019-A1 | STABLE SALTS OF S-ADENOSYLMETHIONINE AND PROCESS FOR THE PREPARATION THEREOF | GNOSIS SPA (IT) | 2009-01-15 | — | — | WO | disclosed |
| US-20080206333-A1 | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine | METHYLATION SCIENCES INTERNATIONAL SRL (BB) | 2008-08-28 | — | — | US | disclosed |
| WO-2008095142-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATIONS OF S-ADENOSYLMETHIONINE | METHYLATION SCIENCES INTERNATIONAL SRL (CA) | 2008-08-07 | — | — | WO | disclosed |
| US-4956173-A | COSMETICS, DRUGS | SOCIETE ANONYME: SANOFI (FR) | 1990-09-11 | — | — | US | disclosed |
| EP-0318393-A1 | Use of ademetionine against ageing of the skin | ELF SANOFI (FR) | 1989-05-31 | — | — | EP | disclosed |
| EP-0141914-B1 | PROCESS FOR PRODUCING STABLE S-ADENOSYL-L-METHIONINE SALTS | BIORESEARCH S.p.A. (IT) | 1987-12-23 | — | — | EP | disclosed |
| US-4621056-A | Process for producing stable sulpho-adenosyl-L-methionine salts | BIORESEARCH S.P.A (IT) | 1986-11-04 | — | — | US | disclosed |
| EP-0141914-A1 | Process for producing stable S-adenosyl-L-methionine salts | BIORESEARCH S.p.A. (IT) | 1985-05-22 | — | — | EP | disclosed |
| US-4028183-A | MULTISTAGE, MULTIZONAL; ATP-METHIONINE-ADENOSYL-TRANSFERASE ON ATP | BIORESEARCH LIMITED (IT) | 1977-06-07 | — | — | US | disclosed |
| US-3954726-A | Double salts of S-adenosil-L-methionine | BIORESEARCH LIMITED (IT) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206333-A1 | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine | MAT2A, MAT1A, AMD1 | ALDH1A1 331/4885SMN1; SMN2 2407/4885LMNA 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.